Skip to main content

MPM Bioimpact LLC

13F filer · CIK 0001687078
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$1.64BU.S. long equity reported on 13F
Positions377 new · 11 closed
Net flow last quarter-$54.7MBuys minus sells
Top 10 positions weight55.3%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202637 positions
CGEMCullinan Therapeutics, Inc.$177M10.81%15.12%+27.2%Q1 2021
AKTSAktis Oncology, Inc.$156M9.50%9.05%Not reportedQ1 2026
LQDALiquidia Corp$111M6.74%1.56%-1.4%Q3 2025
RVMDRevolution Medicines, Inc.$92.2M5.62%0.23%-2.8%Q3 2021
CORTCorcept Therapeutics Inc$67M4.09%0.72%-21.8%Q1 2026
EWTXEdgewise Therapeutics, Inc.$65.9M4.02%1.50%-2.4%Q3 2022
TVTXTravere Therapeutics, Inc.$63.8M3.89%1.19%-0.9%Q3 2021
DBVTDBV Technologies S.A.$60.1M3.67%1.24%-29.7%Q2 2025
TRVITrevi Therapeutics, Inc.$57.3M3.50%2.16%-6.8%Q1 2024
ALMSAlumis Inc.$56.8M3.46%Not reported-15.4%Q4 2025
QUREuniQure N.V.$56.5M3.44%1.77%-10.5%Q4 2022
RAREUltragenyx Pharmaceutical Inc.$47.4M2.89%1.44%Not reportedQ1 2024
RLAYRelay Therapeutics, Inc.$45.2M2.76%1.11%+2.4%Q1 2023
ABVXAbivax S.A.$44.8M2.73%0.43%+213.6%Q4 2025
DYNDyne Therapeutics, Inc.$42.7M2.60%1.16%+36.5%Q2 2025
DNTHDianthus Therapeutics, Inc.$40.9M2.50%0.77%-0.9%Q1 2026
BIOABioAge Labs, Inc.$40.9M2.49%3.64%NewQ2 2026
URGNUroGen Pharma Ltd.$34.3M2.09%1.91%-1.1%Q3 2025
MLTXMoonLake Immunotherapeutics$31.3M1.91%2.18%-11.3%Q2 2023
PVLAPalvella Therapeutics, Inc.$31.2M1.90%1.42%-1.2%Q3 2025
TSHATaysha Gene Therapies, Inc.$30.6M1.87%1.38%Not reportedQ2 2025
SNDXSyndax Pharmaceuticals Inc$29.2M1.78%1.50%-0.5%Q3 2025
GLUEMonte Rosa Therapeutics, Inc.$28.1M1.71%1.36%-1.4%Q4 2025
ZURAZura Bio Ltd$26.4M1.61%4.69%NewQ2 2026
NTRANatera, Inc.$25.1M1.53%0.06%-0.5%Q1 2024
STOKStoke Therapeutics, Inc.$23.7M1.44%1.16%-5.7%Q3 2024
ANLAdlai Nortye Ltd.$22.3M1.36%Not reportedNewQ2 2026
BLTEBelite Bio, Inc$21.1M1.29%0.35%+55.8%Q4 2025
FBRXForte Biosciences, Inc.$21M1.28%4.82%-1.3%Q1 2026
ORICOric Pharmaceuticals, Inc.$20.4M1.24%1.82%+4.3%Q1 2025
TARSTarsus Pharmaceuticals, Inc.$20.3M1.24%0.74%-2.4%Q2 2025
ANNXAnnexon, Inc.$20.2M1.23%2.37%NewQ2 2026
DRUGBright Minds Biosciences Inc.$14.2M0.87%2.65%-4.7%Q4 2025
TRDAEntrada Therapeutics, Inc.$9.22M0.56%3.22%NewQ2 2026
ACRSAclaris Therapeutics, Inc.$5.51M0.34%0.75%+166.0%Q1 2026
CNTXContext Therapeutics Inc.$720K0.04%1.41%-87.8%Q4 2024
HOWLWerewolf Therapeutics, Inc.$28.9K0.00%0.16%-93.4%Q2 2021
Q1 2026Reported May 15, 202641 positions
DBVTDBV Technologies S.A.$109M8.41%1.76%+423.0%Q2 2025
CGEMCullinan Therapeutics, Inc.$109M8.39%12.45%Not reportedQ1 2021
AKTSAktis Oncology, Inc.$86.5M6.68%9.06%NewQ1 2026
LQDALiquidia Corp$53M4.10%1.59%+0.3%Q3 2025
ALMSAlumis Inc.$52.6M4.06%Not reported-0.6%Q4 2025
EWTXEdgewise Therapeutics, Inc.$52.3M4.04%1.55%+0.3%Q3 2022
RVMDRevolution Medicines, Inc.$49.3M3.81%0.25%+0.2%Q3 2021
AGIOAgios Pharmaceuticals, Inc.$44.2M3.41%2.20%+0.2%Q4 2025
CORTCorcept Therapeutics Inc$39.7M3.07%0.93%NewQ1 2026
TRVITrevi Therapeutics, Inc.$39.4M3.04%2.57%+0.4%Q1 2024
DNTHDianthus Therapeutics, Inc.$35.6M2.75%0.78%NewQ1 2026
XENEXenon Pharmaceuticals Inc.$34.2M2.64%0.61%+21.2%Q3 2024
MLTXMoonLake Immunotherapeutics$33.8M2.61%3.44%Not reportedQ2 2023
TVTXTravere Therapeutics, Inc.$33.7M2.60%1.23%Not reportedQ3 2021
EVMNEvommune, Inc.$33.5M2.58%4.04%+1188.1%Q4 2025
CYTKCytokinetics Inc$33M2.54%0.41%Not reportedQ3 2021
SNDXSyndax Pharmaceuticals Inc$31.3M2.42%1.51%+0.2%Q3 2025
CNTXContext Therapeutics Inc.$28M2.16%11.62%Not reportedQ4 2024
FBRXForte Biosciences, Inc.$25.9M2.00%7.19%NewQ1 2026
PVLAPalvella Therapeutics, Inc.$25.7M1.99%1.44%+0.3%Q3 2025
DYNDyne Therapeutics, Inc.$25.5M1.97%0.85%+0.2%Q2 2025
STOKStoke Therapeutics, Inc.$25M1.93%1.23%-0.4%Q3 2024
CRVSCorvus Pharmaceuticals, Inc.$24.5M1.89%1.99%-39.0%Q4 2025
RLAYRelay Therapeutics, Inc.$23.5M1.81%1.25%+5.7%Q1 2023
TARSTarsus Pharmaceuticals, Inc.$23.1M1.79%0.77%+0.3%Q2 2025
ORICOric Pharmaceuticals, Inc.$22.9M1.77%1.74%+0.3%Q1 2025
QUREuniQure N.V.$22.4M1.73%2.17%-0.9%Q4 2022
GLUEMonte Rosa Therapeutics, Inc.$19.4M1.50%1.40%+0.3%Q4 2025
NTRANatera, Inc.$18.6M1.44%0.07%-0.5%Q1 2024
CLYMClimb Bio, Inc.$17.8M1.37%5.43%-2.9%Q4 2025
ARQTArcutis Biotherapeutics, Inc.$17.3M1.34%0.59%+38.2%Q1 2022
URGNUroGen Pharma Ltd.$17M1.31%1.94%+0.3%Q3 2025
DRUGBright Minds Biosciences Inc.$15.5M1.20%2.78%-7.8%Q4 2025
ZYMEZymeworks Inc.$14.2M1.09%0.77%NewQ1 2026
BLTEBelite Bio, Inc$14M1.08%0.22%+0.3%Q4 2025
VRDNViridian Therapeutics, Inc.\DE$12.7M0.98%0.63%Not reportedQ2 2023
ENGNenGene Therapeutics Inc.$12.6M0.97%2.75%+0.2%Q3 2025
ABVXAbivax S.A.$11.9M0.92%0.14%+90.5%Q4 2025
ALLOAllogene Therapeutics, Inc.$5.47M0.42%0.92%NewQ1 2026
ACRSAclaris Therapeutics, Inc.$1.47M0.11%0.28%NewQ1 2026
HOWLWerewolf Therapeutics, Inc.$1.01M0.08%2.49%-13.3%Q2 2021
Q4 2025Reported Feb 17, 202638 positions
CGEMCullinan Therapeutics, Inc.$79.2M9.06%12.70%Not reportedQ1 2021
MDGLMadrigal Pharmaceuticals, Inc.$56.4M6.45%0.42%-3.6%Q2 2022
LQDALiquidia Corp$48.3M5.53%1.61%+600.4%Q3 2025
TRVITrevi Therapeutics, Inc.$41.2M4.71%2.56%-3.5%Q1 2024
EWTXEdgewise Therapeutics, Inc.$41.1M4.70%1.56%-3.8%Q3 2022
RVMDRevolution Medicines, Inc.$40.3M4.61%0.26%+60.2%Q3 2021
AGIOAgios Pharmaceuticals, Inc.$35.5M4.06%2.23%NewQ4 2025
QUREuniQure N.V.$33.1M3.78%2.22%Not reportedQ4 2022
PTCTPTC Therapeutics, Inc.$32.7M3.74%0.53%-1.9%Q3 2024
SNDXSyndax Pharmaceuticals Inc$28.1M3.22%1.53%-2.8%Q3 2025
DYNDyne Therapeutics, Inc.$27.5M3.15%0.85%-2.8%Q2 2025
TARSTarsus Pharmaceuticals, Inc.$26.9M3.08%0.77%-3.7%Q2 2025
STOKStoke Therapeutics, Inc.$24.4M2.80%1.31%-2.5%Q3 2024
ALMSAlumis Inc.$23.4M2.68%Not reportedNewQ4 2025
URGNUroGen Pharma Ltd.$22M2.52%1.95%+597.3%Q3 2025
XENEXenon Pharmaceuticals Inc.$21.8M2.49%0.61%-3.5%Q3 2024
PVLAPalvella Therapeutics, Inc.$21.5M2.46%1.66%+205.2%Q3 2025
NTRANatera, Inc.$21.4M2.45%0.07%-5.4%Q1 2024
CRVSCorvus Pharmaceuticals, Inc.$21.1M2.42%3.67%NewQ4 2025
DBVTDBV Technologies S.A.$19.1M2.19%0.59%-5.5%Q2 2025
RLAYRelay Therapeutics, Inc.$18.9M2.16%1.28%-2.2%Q1 2023
GLUEMonte Rosa Therapeutics, Inc.$18.4M2.11%1.79%NewQ4 2025
DRUGBright Minds Biosciences Inc.$18M2.06%3.01%NewQ4 2025
PTGXProtagonist Therapeutics, Inc$17.4M1.99%0.32%NewQ4 2025
ENGNenGene Therapeutics Inc.$16.6M1.90%2.75%+247.1%Q3 2025
CNTXContext Therapeutics Inc.$15.7M1.80%11.62%-27.4%Q4 2024
ARQTArcutis Biotherapeutics, Inc.$15.4M1.77%0.43%Not reportedQ1 2022
VTYXVentyx Biosciences, Inc.$14.8M1.69%2.30%Not reportedQ2 2023
ORICOric Pharmaceuticals, Inc.$14.7M1.68%1.83%+4.0%Q1 2025
BLTEBelite Bio, Inc$14M1.61%0.22%NewQ4 2025
RAPTRAPT Therapeutics, Inc.$13.5M1.54%1.44%NewQ4 2025
CLYMClimb Bio, Inc.$10.7M1.22%5.59%NewQ4 2025
ABVXAbivax S.A.$7.59M0.87%0.07%NewQ4 2025
RCKTRocket Pharmaceuticals, Inc.$5.57M0.64%1.46%-59.4%Q3 2024
MAZEMaze Therapeutics, Inc.$3.36M0.38%0.16%NewQ4 2025
EVMNEvommune, Inc.$1.93M0.22%0.36%NewQ4 2025
SRPTSarepta Therapeutics, Inc.$1.51M0.17%0.07%-90.0%Q2 2025
HOWLWerewolf Therapeutics, Inc.$884K0.10%2.87%-42.2%Q2 2021
Q3 2025Reported Nov 14, 202540 positions
MDGLMadrigal Pharmaceuticals, Inc.$46.1M7.54%0.44%Not reportedQ2 2022
CGEMCullinan Therapeutics, Inc.$45.4M7.42%12.95%Not reportedQ1 2021
RNAMAvidity Biosciences, Inc.$33.1M5.42%0.52%Not reportedQ2 2024
TRVITrevi Therapeutics, Inc.$31.2M5.10%2.66%Not reportedQ1 2024
EWTXEdgewise Therapeutics, Inc.$27.9M4.57%1.63%Not reportedQ3 2022
PTCTPTC Therapeutics, Inc.$26.9M4.41%0.55%Not reportedQ3 2024
ZLABZai Lab Ltd$25.3M4.13%0.07%Not reportedQ4 2024
SNDXSyndax Pharmaceuticals Inc$21.2M3.46%1.58%NewQ3 2025
ORICOric Pharmaceuticals, Inc.$20.8M3.40%1.78%Not reportedQ1 2025
TARSTarsus Pharmaceuticals, Inc.$20.3M3.32%0.80%Not reportedQ2 2025
XENEXenon Pharmaceuticals Inc.$20.2M3.31%0.65%+55.7%Q3 2024
STOKStoke Therapeutics, Inc.$18.6M3.04%1.43%Not reportedQ3 2024
DYNDyne Therapeutics, Inc.$18.3M3.00%1.01%Not reportedQ2 2025
CMPXCompass Therapeutics, Inc.$17.8M2.91%2.86%-9.7%Q1 2024
ALKSAlkermes plc.$16.5M2.70%0.33%Not reportedQ2 2024
VERAVera Therapeutics, Inc.$16.4M2.68%0.88%Not reportedQ4 2024
NTRANatera, Inc.$15.9M2.61%0.07%Not reportedQ1 2024
JANXJanux Therapeutics, Inc.$15M2.46%1.02%Not reportedQ3 2024
RVMDRevolution Medicines, Inc.$14.7M2.41%0.17%Not reportedQ3 2021
CNTXContext Therapeutics Inc.$14.2M2.33%16.01%Not reportedQ4 2024
SRPTSarepta Therapeutics, Inc.$13.5M2.21%0.67%+117.6%Q2 2025
SPRYARS Pharmaceuticals, Inc.$13.1M2.14%1.32%Not reportedQ1 2025
RCKTRocket Pharmaceuticals, Inc.$12.7M2.08%3.61%0.0%Q3 2024
RLAYRelay Therapeutics, Inc.$11.9M1.95%1.32%Not reportedQ1 2023
RAREUltragenyx Pharmaceutical Inc.$11.9M1.95%0.41%Not reportedQ1 2024
WVEWave Life Sciences, Inc.$11M1.80%0.94%Not reportedQ3 2024
DBVTDBV Technologies S.A.$10.5M1.73%0.77%Not reportedQ2 2025
SLNOSoleno Therapeutics Inc$10.1M1.66%0.28%+200.0%Q2 2025
SLDBSolid Biosciences Inc.$10.1M1.65%2.10%Not reportedQ3 2024
AKBAAkebia Therapeutics, Inc.$7.89M1.29%1.09%Not reportedQ2 2025
HOWLWerewolf Therapeutics, Inc.$4.75M0.78%5.10%Not reportedQ2 2021
LQDALiquidia Corp$4.55M0.74%0.23%NewQ3 2025
PVLAPalvella Therapeutics, Inc.$4.23M0.69%0.61%NewQ3 2025
DSGNDesign Therapeutics, Inc.$4.18M0.68%0.97%Not reportedQ4 2024
RNACCartesian Therapeutics, Inc.$3.88M0.64%1.46%-44.6%Q2 2024
ENGNenGene Therapeutics Inc.$3.62M0.59%1.04%NewQ3 2025
URGNUroGen Pharma Ltd.$2.69M0.44%0.29%NewQ3 2025
RAPPRapport Therapeutics, Inc.$2.13M0.35%0.15%NewQ3 2025
RPTXRepare Therapeutics Inc.$1.44M0.24%1.91%Not reportedQ2 2020
ASMBAssembly Biosciences, Inc.$1.02M0.17%0.25%NewQ3 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.